Based on our study, targeting this oncogenic mechanism in a subset of ER- breast cancers with high pEZH2(T367) expression using combined EZH2 and p38 inhibition may offer a therapeutic opportunity to interrupt breast cancer metastasis to distant sites. The gene discussed is MAPK14; the disease is breast cancer.